Literature DB >> 33080112

A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic.

K Hansel1, A Zangrilli2, L Bianchi1, K Peris3, A Chiricozzi3, A Offidani4, F Diotallevi4, M C Fargnoli5, M Esposito5, P Amerio6, G Gualdi6, L Bianchi1, L Stingeni1.   

Abstract

Entities:  

Year:  2020        PMID： 33080112     DOI： 10.1111/jdv.17003

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN： 0926-9959            Impact factor:   6.166


× No keyword cloud information.
  10 in total

1.  Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study.

Authors:  Riccardo G Borroni; Piergiorgio Malagoli; Luigi Gargiulo; Mario Valenti; Giulia Pavia; Paola Facheris; Emanuela Morenghi; Isotta Giunipero Di Corteranzo; Alessandra Narcisi; Michela Ortoncelli; Paolo Dapavo; Antonio Costanzo
Journal:  Acta Derm Venereol       Date:  2021-11-30       Impact factor: 3.875

2.  Risankizumab shows high efficacy and maintenance in improvement of response until week 52.

Authors:  Luca Mastorino; Sara Susca; Matteo Megna; Niccolò Siliquini; Pietro Quaglino; Michela Ortoncelli; Gianluca Avallone; Marco Rubatto; Gabriella Fabbrocini; Paolo Dapavo; Simone Ribero
Journal:  Dermatol Ther       Date:  2022-02-28       Impact factor: 3.858

3.  Risankizumab for the treatment of moderate-to-severe psoriasis: A multicenter, retrospective, 1 year real-life study.

Authors:  Giacomo Caldarola; Arianna Zangrilli; Nicoletta Bernardini; Mauro Bavetta; Clara De Simone; Dario Graceffa; Claudio Bonifati; Sara Faleri; Domenico Giordano; Marco Mariani; Adriana Micheli; Gaia Moretta; Gianluca Pagnanelli; Vincenzo Panasiti; Alessia Provini; Antonio Richetta; Ketty Peris; Luca Bianchi
Journal:  Dermatol Ther       Date:  2022-04-13       Impact factor: 3.858

Review 4.  A Molecular Perspective on the Potential Benefits of Metformin for the Treatment of Inflammatory Skin Disorders.

Authors:  Ji-Eun Chang; Min Sik Choi
Journal:  Int J Mol Sci       Date:  2020-11-25       Impact factor: 5.923

Review 5.  Biologics for Psoriasis During the COVID-19 Pandemic.

Authors:  Huanhuan Zeng; Siyu Wang; Ling Chen; Zhu Shen
Journal:  Front Med (Lausanne)       Date:  2021-12-06

Review 6.  A Peek into Pandora's Box: COVID-19 and Neurodegeneration.

Authors:  Abhishek Chandra; Ashu Johri
Journal:  Brain Sci       Date:  2022-01-30

Review 7.  Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence.

Authors:  Angelo Ruggiero; Vincenzo Picone; Fabrizio Martora; Gabriella Fabbrocini; Matteo Megna
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-08-16

8.  Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective study.

Authors:  Angelo Ruggiero; Gabriella Fabbrocini; Eleonora Cinelli; Matteo Megna
Journal:  Dermatol Ther       Date:  2021-11-30       Impact factor: 3.858

9.  Efficacy of Tildrakizumab Across Different Body Weights in Moderate-to-Severe Psoriasis Over 5 Years: Pooled Analyses from the reSURFACE Pivotal Studies.

Authors:  Diamant Thaçi; Sascha Gerdes; Kristian Gaarn Du Jardin; Jean-Luc Perrot; Lluís Puig
Journal:  Dermatol Ther (Heidelb)       Date:  2022-09-13

10.  Risankizumab treatment in psoriasis patients who failed anti-IL17: A 52-week real-life study.

Authors:  Matteo Megna; Luca Potestio; Angelo Ruggiero; Elisa Camela; Gabriella Fabbrocini
Journal:  Dermatol Ther       Date:  2022-04-26       Impact factor: 3.858
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.